Galera Therapeutics (GRTX) AI Stock Analysis

• Market Cap: $3.41M
• Dividend Yield: N/A
• Average Volume (3M): 63.57K
• Price to Earnings (P/E): <0.1
• Beta (1Y): 0.73
• Revenue Growth: N/A
• EPS Growth: 63.89%
• Country: US
• Employees: 3
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 75,462,390
• 10 Day Avg. Volume: 87,114
• 30 Day Avg. Volume: 63,573
• PEG Ratio: >-0.01
• Price to Book (P/B): 0.55
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -0.87
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 1.17
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $0.05 ▲(145.00% Upside)
• Action: Reiterated Date: 03/20/26
• Date: Action: Reiterated 03/20/26

Overall score reflects very weak fundamentals (pre-revenue profile, persistent operating losses, and historically negative cash flows) partially offset by improved balance-sheet positioning in 2025 and constructive technical momentum (price above key moving averages with positive MACD). Valuation appears optically cheap on P/E, but its signal quality is limited by non-operating earnings and lack of revenue.

Positive Factors

Balance-sheet deleveraging

Elimination of reported debt and a shift to small positive equity materially lowers near-term solvency risk and reduces refinancing pressure. This durable repair to capitalization improves flexibility for 2–6 months+ planning, making incremental financing or program funding less urgent.

Capital-structure flexibility

Board discretion to convert Series B preferred shares creates a structural tool to simplify capital structure and enable quicker strategic financing or share-class consolidation. That flexibility can reduce stakeholder conflict and facilitate durable execution of financing or M&A strategies.

Retention of key financial officer

Securing the chief accounting officer supports continuity and reliable financial reporting during critical periods. Stable financial leadership reduces operational and regulatory risk around filings and financing activities, strengthening governance over the medium term.

Negative Factors

Pre-revenue operations

A multi-year pre-revenue profile with persistently negative operating results means the company must rely on external capital to fund R&D and operations. This structural dependence increases dilution and execution risk for clinical programs over the next several quarters.

Poor cash generation

Sustained negative operating and free cash flows indicate the company is not self-funding and remains vulnerable to funding gaps. Absent durable positive cash generation, management will need fresh capital for operations and trials, making long-term program continuity contingent on financing.

Thin capital base and small scale

A small asset/equity base and a three-person workforce constrain internal execution capacity and absorbable shocks. Limited scale raises reliance on outsourcing and partners, increasing execution and operational risk for clinical development over a multi-month horizon.

Galera Therapeutics Business Overview & Revenue Model

Company Description

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

How the Company Makes Money

null

Galera Therapeutics Financial Statement Overview

Summary

Financial performance is very weak: revenue is $0 across 2020–2025 with negative EBIT/EBITDA every year and a history of material cash burn. The 2025 balance-sheet reset (debt reduced to $0 and equity turning slightly positive) helps reduce financial risk versus 2024, but earnings quality is questionable given negative operating results and a net income spike not supported by operating cash flow.

Income Statement

Operating performance remains weak: revenue is consistently $0 across 2020–2025, while EBIT and EBITDA are negative in every year shown (reflecting ongoing R&D/operating burn). Losses were very large from 2020–2024, with EBIT improving in 2025 vs. prior years, but the 2025 net income swing to a large profit appears non-operating and not supported by core earnings (since EBIT stayed negative). Overall, profitability quality and sustainability are low despite the one-year net income spike.

Balance Sheet

Leverage and capitalization look stressed. Equity is deeply negative from 2021–2024, improving to a small positive level in 2025, which is a meaningful repair but still leaves a thin capital cushion (assets are modest at ~$7.2M with equity ~$4.0M in 2025). Debt is $0 in 2025 after being extremely high in 2024 (~$151.0M), suggesting a major deleveraging/restructuring; that reduces balance-sheet risk, but the historical negative equity and sharp balance-sheet shifts highlight instability.

Cash Flow

Cash generation is poor: operating cash flow and free cash flow are materially negative from 2020–2024, consistent with a pre-revenue biotech consuming cash. While burn improved in 2024 versus 2023 (less negative), cash flow remains negative overall, and 2025 shows $0 operating and free cash flow, which does not demonstrate durable positive cash generation. The gap between the 2025 net income and cash flow also raises earnings-quality concerns.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-3.84M	-259.00K	-114.00K	-778.00K
EBITDA	-2.54M	-20.16M	-70.24M	-50.61M	-72.56M
Net Income	149.05M	-18.96M	-59.08M	-62.22M	-80.53M
Balance Sheet
Total Assets	7.20M	10.10M	26.14M	44.04M	83.31M
Cash, Cash Equivalents and Short-Term Investments	6.38M	8.29M	18.26M	31.60M	71.22M
Total Debt	0.00	151.05M	1.25M	44.00K	302.00K
Total Liabilities	645.00K	153.77M	157.33M	153.22M	141.31M
Stockholders Equity	3.97M	-143.67M	-131.19M	-109.18M	-58.00M
Cash Flow
Free Cash Flow	0.00	-12.14M	-44.91M	-43.45M	-68.24M
Operating Cash Flow	0.00	-12.14M	-44.85M	-43.43M	-67.96M
Investing Cash Flow	3.50M	-46.00K	27.29M	23.99M	5.24M
Financing Cash Flow	635.00K	2.22M	31.50M	3.89M	66.71M

Galera Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.02
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GRTX, the sentiment is Neutral. The current price of 0.02 is below the 20-day moving average (MA) of 0.04, below the 50-day MA of 0.03, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 51.62 is Neutral, neither overbought nor oversold. The STOCH value of 31.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GRTX.

Galera Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EVAX	58 Neutral	$33.36M	―	-61.62%	―	4455.07%	77.31%
GRTX	52 Neutral	$3.41M	0.01	13.71%	―	―	63.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SCNI	49 Neutral	$603.58K	-0.24	―	―	178.82%	-4121.10%
ONCO	33 Underperform	$2.22M	-0.10	-263.57%	―	-34.58%	96.41%

Galera Therapeutics Corporate Events

Galera Therapeutics Updates Preferred Stock Conversion Provisions

On February 12, 2026, Galera Therapeutics, Inc. filed a Certificate of Amendment with the Delaware Secretary of State to modify the terms of its Series B Non-Voting Convertible Preferred Stock. The amendment permits the company’s board of directors, at its sole discretion, to convert some or all outstanding shares of this preferred stock into common stock based on the existing conversion ratio, following approval by the board and unanimous consent of Series B holders.

This governance change gives Galera greater flexibility to manage its equity capital structure and potentially streamline its share classes over time. By securing unanimous written consent from Series B preferred shareholders, the company has reduced the risk of stakeholder conflict around conversions while positioning itself to act quickly if strategic, financing, or market conditions make such conversions advantageous.

The most recent analyst rating on (GRTX) stock is a Hold with a $0.02 price target. To see the full list of analyst forecasts on Galera Therapeutics stock, see the GRTX Stock Forecast page.

Galera Therapeutics Grants Retention Bonus to Key Officer

On February 6, 2026, Galera Therapeutics, Inc. entered into a letter agreement with Chief Accounting Officer, Treasurer, and Secretary Joel Sussman that provides retention-based cash bonus payments tied to the timely completion and filing of certain company reporting obligations. Under the agreement, Sussman can receive up to $250,000 in aggregate retention bonuses, which will offset any severance otherwise owed under his employment contract, and any unpaid portion becomes payable if he is involuntarily terminated without cause or resigns for good reason, underscoring the company’s emphasis on stable financial leadership and reliable reporting during this period.

The most recent analyst rating on (GRTX) stock is a Hold with a $0.02 price target. To see the full list of analyst forecasts on Galera Therapeutics stock, see the GRTX Stock Forecast page.